Rain Therapeutics Inc.: insider trades · United States · SEC (Form 4)

About Rain Therapeutics Inc.

Rain Therapeutics Inc. is a United States-based biopharmaceutical company focused on precision oncology. The company was incorporated in Delaware in April 2017 and its principal operations were reported in Newark, California, United States. SEC filings describe a strategy built around genetically selected cancer patients, meaning the company has aimed to match therapies to the underlying biology of tumors rather than relying only on tumor histology. In investment terms, that places Rain Therapeutics in the highly competitive clinical-stage biotech universe, where value creation depends on clinical execution, regulatory progress, and the ability to finance long development cycles. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724979/000155837023003331/rain-20221231x10k.htm?utm_source=openai)) The company’s lead product candidate has been milademetan, also known as RAIN-32, an oral inhibitor of the MDM2-p53 complex designed to reactivate p53, a central tumor-suppressor pathway. Rain also disclosed a preclinical program focused on RAD52 inhibition, suggesting an effort to build a broader oncology platform rather than relying on a single asset. Competitive positioning is therefore driven primarily by scientific differentiation, trial data quality, and potential partnering optionality. Rain Therapeutics competes against both large pharmaceutical groups and a long list of oncology-focused biotech companies pursuing genetically defined cancer indications. As a result, the company’s market position has been more about pipeline credibility than commercial scale. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724979/000155837023003331/rain-20221231x10k.htm?utm_source=openai)) Geographically, the business has been centered in the United States, with an additional wholly owned Australian subsidiary disclosed in SEC filings. For investors, it is also important that Rain Therapeutics is associated with the U.S. NASDAQ market and operates under the disclosure framework of the SEC, including Form 4 insider-transaction reporting. The SEC record also shows that the company changed its name to Rain Oncology Inc. in late 2022, which indicates a corporate and strategic evolution over time. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724979/000155837023014498/R7.htm?utm_source=openai)) As for recent developments, the sources reviewed confirm continued SEC filing activity, but they do not provide enough current, company-specific operational detail to responsibly state fresh numerical metrics or major pipeline milestones without risking error. Accordingly, the most accurate characterization is that Rain Therapeutics remains a U.S. clinical-stage oncology biotech whose investment case is highly event-driven and dependent on trial readouts, regulatory updates, financing needs, and insider-trading disclosures filed with the SEC. For French-speaking investors, this is the type of NASDAQ-listed healthcare name where the upside thesis is tied to clinical differentiation, while the downside risk remains elevated because pipeline failure or capital constraints can materially impact equity value. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1724979/000155837023003331/rain-20221231x10k.htm?utm_source=openai))